Nilotinib Teva Uk

Nilotinib, the active ingredient in Nilotinib Teva Uk, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in its chronic, accelerated and blast phases, targeting malignant cells that express the BCR‑ABL fusion protein.

GNH USA supplies Nilotinib Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Nilotinib is indicated for the treatment of chronic myeloid leukemia, a BCR‑ABL driven hematologic malignancy.

- Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves hematologic and cytogenetic response. - Chronic myeloid leukemia (accelerated phase): helps achieve molecular remission and disease control. - Chronic myeloid leukemia (blast crisis): provides therapeutic benefit when other options are limited.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Rash - Headache - Arthralgia

Serious or Rare Side Effects: - QT interval prolongation - Pancreatitis - Elevated liver enzymes (hepatotoxicity) - Severe neutropenia or thrombocytopenia - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Cardiac arrhythmias

When prescribing Nilotinib, clinicians should observe several safety measures to minimize risk.

- Monitor cardiac function: perform baseline ECG and periodic checks for QT prolongation. - Monitor blood counts: conduct regular complete blood count assessments for neutropenia or thrombocytopenia. - Monitor liver enzymes: evaluate hepatic function before and during therapy. - Avoid strong CYP3A4 inhibitors: concomitant use may increase nilotinib exposure and toxicity. - Store at below 25°C: keep in the original pack, protect from moisture.

Nilotinib interacts with several medicines that can alter its plasma concentration or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and increase toxicity. - QT‑prolonging agents (e.g., quinidine, amiodarone): additive risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: can reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib concentrations and reduce efficacy. - Warfarin: may require INR monitoring due to potential interaction.